Kinetics of inhibition of replication of vesicular stomatitis virus in blood mononuclear cells of horses after in vitro and in vivo treatment with recombinant equine interferon-beta 1.

The research discusses how Recombinant equine interferon-beta 1 (reqIFN-beta 1) has been found to trigger an antiviral state in the blood mononuclear cells in horses, offering maximum protection against the replication of vesicular stomatitis virus approximately six hours after treatment.

Induction of Antiviral State

• The study aimed to understand how reqIFN-beta 1 affects the replication of vesicular stomatitis virus in horses.
• It was found that the reqIFN-beta 1 induces an antiviral state in the blood mononuclear cells (BMC) of horses offering protection against the virus. This was observed in both in vitro and in vivo conditions.
• The maximum protective effect was noticed six hours after the treatment using this interferon.

Dose-Dependent Efficacy

• The effectiveness of this response was found to be dose-dependent. The larger the dose of IFN applied, the longer the duration of the protective effect.
• However, the continued availability of the reqIFN-beta 1 in the culture of BMC for up to 48 hours did not extend the duration of the antiviral state, suggesting that the initial dose is crucial.

Measurement and Monitoring

• The study indicates that measuring the impact of IFN in vivo can be simplified to two tests: one before and one six hours after the interferon application.
• All succeeding tests can then be carried out in vitro, simplifying the monitoring process considerably while being accurate.

Multiple Administration Effect

• Researchers found that the repeated administration of reqIFN-beta 1 did not enhance the duration of the protective phase after each administration.
• Once again showing that the duration of the antiviral state depends solely on the dose of the reqIFN-beta 1 administered initially.